

Miles Andrews

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7770611/publications.pdf>

Version: 2024-02-01

62
papers

7,515
citations

218677

26
h-index

175258

52
g-index

68
all docs

68
docs citations

68
times ranked

12786
citing authors

#	ARTICLE	IF	CITATIONS
1	Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. <i>Science</i> , 2018, 359, 97-103.	12.6	3,126
2	Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. <i>Cell</i> , 2017, 170, 1120-1133.e17.	28.9	960
3	Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. <i>Nature Medicine</i> , 2018, 24, 1649-1654.	30.7	592
4	Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. <i>Science</i> , 2021, 374, 1632-1640.	12.6	369
5	Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , 2018, 19, 181-193.	10.7	233
6	Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 22699-22709.	7.1	226
7	Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. <i>Nature Medicine</i> , 2021, 27, 1432-1441.	30.7	216
8	Hallmarks of response to immune checkpoint blockade. <i>British Journal of Cancer</i> , 2017, 117, 1-7.	6.4	194
9	Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade. <i>Cell Research</i> , 2019, 29, 846-861.	12.0	160
10	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. <i>Lancet Oncology</i> , 2019, 20, e378-e389.	10.7	155
11	MEK Inhibition, Alone or in Combination with BRAF Inhibition, Affects Multiple Functions of Isolated Normal Human Lymphocytes and Dendritic Cells. <i>Cancer Immunology Research</i> , 2014, 2, 351-360.	3.4	122
12	Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy. <i>British Journal of Cancer</i> , 2016, 114, 1084-1089.	6.4	113
13	Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases. <i>British Journal of Cancer</i> , 2017, 116, 1558-1563.	6.4	91
14	Apocynin but Not Allopurinol Prevents and Reverses Adrenocorticotrophic Hormone-Induced Hypertension in the Rat. <i>American Journal of Hypertension</i> , 2005, 18, 910-916.	2.0	81
15	The nitric oxide system in glucocorticoid-induced hypertension. <i>Journal of Hypertension</i> , 2002, 20, 1035-1043.	0.5	77
16	The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression. <i>Clinical Cancer Research</i> , 2018, 24, 3366-3376.	7.0	73
17	Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure. <i>EMBO Molecular Medicine</i> , 2017, 9, 1011-1029.	6.9	63
18	Human perforin mutations and susceptibility to multiple primary cancers. <i>Oncotarget</i> , 2013, 2, e24185.	4.6	57

#	ARTICLE	IF	CITATIONS
19	Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. <i>Nature</i> , 2022, 606, 797-803.	27.8	54
20	BRAF Inhibitor-Driven Tumor Proliferation in a <i>KRAS</i> -Mutated Colon Carcinoma Is Not Overcome by MEK1/2 Inhibition. <i>Journal of Clinical Oncology</i> , 2013, 31, e448-e451.	1.6	51
21	Abstract 2838: The gut microbiome (GM) and immunotherapy response are influenced by host lifestyle factors. <i>Cancer Research</i> , 2019, 79, 2838-2838.	0.9	50
22	Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional <i>Bacillus Calmette-Guérin</i> followed by Ipilimumab in Patients with Advanced Metastatic Melanoma. <i>Frontiers in Immunology</i> , 2018, 9, 411.	4.8	49
23	PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation. <i>Molecular Cancer</i> , 2017, 16, 112.	19.2	44
24	Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma. <i>Australasian Journal of Dermatology</i> , 2017, 58, e109-e112.	0.7	30
25	Effects of Epithelial to Mesenchymal Transition on T Cell Targeting of Melanoma Cells. <i>Frontiers in Oncology</i> , 2014, 4, 367.	2.8	29
26	Cancer Evolution during Immunotherapy. <i>Cell</i> , 2017, 171, 740-742.	28.9	28
27	Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma. <i>Nature Communications</i> , 2020, 11, 853.	12.8	23
28	Systems analysis identifies miR-29b regulation of invasiveness in melanoma. <i>Molecular Cancer</i> , 2016, 15, 72.	19.2	21
29	Concepts Collide: Genomic, Immune, and Microbial Influences on the Tumor Microenvironment and Response to Cancer Therapy. <i>Frontiers in Immunology</i> , 2018, 9, 946.	4.8	19
30	Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2015, 40, 121-123.	1.5	17
31	Evolving role of tumor antigens for future melanoma therapies. <i>Future Oncology</i> , 2014, 10, 1457-1468.	2.4	15
32	Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma. <i>Nature Communications</i> , 2020, 11, 1839.	12.8	15
33	The kinase inhibitors dabrafenib and trametinib affect isolated immune cell populations. <i>OncImmunology</i> , 2014, 3, e946367.	4.6	13
34	Immunotherapy resistance: the answers lie ahead "not in front" of us. , 2017, 5, 10.		13
35	Patterns of care for metastatic renal cell carcinoma in Australia. <i>BJU International</i> , 2015, 116, 36-41.	2.5	12
36	Nitric Oxide Donation Lowers Blood Pressure in Adrenocorticotrophic Hormone-Induced Hypertensive Rats. <i>Clinical and Experimental Hypertension</i> , 2004, 26, 499-509.	1.3	10

#	ARTICLE	IF	CITATIONS
37	Adrenocorticotrophic hormone, blood pressure, and serum erythropoietin concentrations in the rat. American Journal of Hypertension, 2004, 17, 457-461.	2.0	9
38	Multi-modal molecular programs regulate melanoma cell state. Nature Communications, 2022, 13, .	12.8	9
39	Antioxidant Vitamins and Adrenocorticotrophic Hormone-Induced Hypertension in Rats. Clinical and Experimental Hypertension, 2007, 29, 465-478.	1.3	7
40	The good, the (not so) bad and the ugly of immune homeostasis in melanoma. Immunology and Cell Biology, 2018, 96, 497-506.	2.3	7
41	A pilot study of intrahepatic yttriumâ€90 microsphere radioembolization in combination with intravenous cisplatin for uveal melanoma liverâ€only metastases. Cancer Reports, 2019, 2, e1183.	1.4	7
42	Identification of MicroRNAâ€™mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes. Cancers, 2021, 13, 5301.	3.7	7
43	Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in <i>Braf</i>-mutated melanoma. OncoImmunology, 2021, 10, 1992880.	4.6	7
44	Characterization of the treatment-naïve immune microenvironment in melanoma with <i>BRAF</i> mutation. , 2022, 10, e004095.		7
45	A single-centre experience of patients with metastatic melanoma enrolled in a dabrafenib named patient programme. Melanoma Research, 2014, 24, 144-149.	1.2	6
46	Abstract 2838: The gut microbiome (GM) and immunotherapy response are influenced by host lifestyle factors. , 2019, , .		6
47	MEK inhibition, alone or in combination with BRAF inhibition, impairs multiple functions of isolated normal human lymphocytes and dendritic cells. , 2013, 1, .		4
48	Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma. Clinical Cancer Research, 2015, 21, 5222-5234.	7.0	4
49	Non-HIV-associated Kaposi sarcoma in an immunosuppressed melanoma patient treated with dabrafenib. Journal of Clinical Pharmacy and Therapeutics, 2016, 41, 354-356.	1.5	3
50	Abstract 1493: Therapeutic efficacy and tolerability of combined immune checkpoint blockade in metastatic melanoma patients is influenced by the gut microbiome. Cancer Research, 2019, 79, 1493-1493.	0.9	3
51	Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatment. Expert Review of Clinical Immunology, 2014, 10, 1107-1123.	3.0	2
52	Updated efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in metastatic melanoma patients previously treated with anti-PD-1 therapy. , 2015, 3, P126.		2
53	Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases. Annals of Oncology, 2016, 27, vi382.	1.2	2
54	Abstract 3776: Spatially resolved immunogenomic analyses reveal diverse sub tumoral microenvironments in the context of melanoma immunotherapy. , 2019, , .		2

#	ARTICLE	IF	CITATIONS
55	Reply to "Comment on "Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy". British Journal of Cancer, 2017, 116, e15-e15.	6.4	1
56	Abstract CT156: Novel neoadjuvant targeted therapy trial yields insight into molecular mechanisms of response. Cancer Research, 2017, 77, CT156-CT156.	0.9	1
57	Predictors of Response to Immune Checkpoint Blockade. , 2018, , 525-544.		0
58	A pilot study of intrahepatic Yttrium-90 microsphere radioembolisation in combination with intravenous cisplatin for uveal melanoma liver-only metastases. Annals of Oncology, 2018, 29, ix105.	1.2	0
59	Abstract 2357: Identification of microRNAs associated with melanoma immunity and immunotherapy outcome. , 2019, , .		0
60	Abstract 3776: Spatially resolved immunogenomic analyses reveal diverse sub tumoral microenvironments in the context of melanoma immunotherapy. , 2019, , .		0
61	Abstract 5704: Pan-cancer genomic characterization of patient-matched primary, extracranial, and brain metastases. , 2020, , .		0
62	Abstract 2357: Identification of microRNAs associated with melanoma immunity and immunotherapy outcome. , 2019, , .		0